Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-Nitrosylation Therapy in Severe Covid-19
NCT04528771Phase 1Withdrawn
- Start
- Aug 2021
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial in coronavirus disease 2019 (COVID-19) comparing SNO with Placebo (2 arms). Primary endpoints: Treatment Emergent Adverse Events at 30 days, Frequency of Intubation at 30 days and 1 more. Planned start Aug 2021; status: withdrawn.
02
Drugs
ethyl nitrite
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04528771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04528771.